Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | MLNR | O43193 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31281225 | 0.99 | PPARG (0.44) | PPARGPPARDPPARAMLNRCYP2D6 | |
| SCHEMBL19423659 | 0.92 | PNMT (0.42) | PPARGPPARDPPARA | |
| SCHEMBL22504328 | 0.92 | PLAU (0.44) | PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL22494232 | 0.83 | MLNR (0.42) | PPARGPPARDMLNRCYP2D6HTR2C | |
| Hydrochloric Acid SCHEMBL22494233 | 0.83 | MLNR (0.42) | PPARGPPARDMLNRCYP2D6HTR2C | |
| SCHEMBL20509999 | 0.81 | PPARG (0.44) | PPARGPPARDPPARA | |
| SCHEMBL20509998 | 0.81 | PPARG (0.44) | PPARGPPARDPPARA | |
| SCHEMBL31173467 | 0.79 | PLAU (0.42) | MLNRCYP2D6 | |
| SCHEMBL20196425 | 0.78 | PPARG (0.53) | PPARGPPARDPPARA | |
| SCHEMBL23420942 | 0.78 | HTR2C (0.47) | MLNRCYP2D6HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | CALDAN THERAPEUTICS LTD (GB) | 2022-01-11 | — | — | US | disclosed |
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD. (GB) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317619-A1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | GPR119, GPR84, GPR65 | PPARG 62/4885PPARD 57/4885PPARA 233/4885 |
| US-11220483-B2 | Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators | GPR119, GPR84, GPR65 | PPARG 63/4885PPARD 56/4885PPARA 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.